In September 2019, the FDA announced concerns that the prescription and OTC medication, Zantac could cause testicular cancer in children. This announcement came after an online pharmacy tested Zantac tablets and found a cancer-causing chemical, NDMA, at levels up to 3,000 times greater than the FDA’s legally allowable limit.
Zantac & NDMA
Zantac (Ranitidine) decreases the amount of acid created by the stomach. The FDA approved OTC ranitidine to prevent and relieve heartburn, and prescription ranitidine is approved for a number of uses, including treatment and prevention of ulcers of the stomach and intestines, and also the treatment of gastroesophageal reflux disease.
The carcinogenic chemical in Zantac (ranitidine) is called N-nitrosodimethylamine (NDMA). The FDA, the U.S. Environmental Protection Agency (EPA) and also the World Health Organization (WHO) all classify NDMA as a carcinogen (a substance that has the potential to cause cancer).
NDMA is a semi-volatile organic chemical that belongs to a family of chemicals known as N-nitrosamines. According to the EPA, N-nitrosamines are “a family of potent carcinogens.” There is a 96 ng daily limit of NDMA. However, recent testing of Zantac found more than 2,500,000 ng of NDMA in a Zantac 150 mg tablet, the dosage countless people take every day.